InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Blasticidin | The origin of long-chain fatty acids required for de novo ether lipid/plasmal... | 2023 | J Lipid Res. | Chornyi S. et al. | DOI: 10.1016/j.jlr.2023.100364 |
| Murine Anti-PD-L1 mAb | Tumor-targeted superantigens produce curative tumor immunity with induction o... | 2023 | J Transl Med. | Azulay M. et al. | DOI: 10.1186/s12967-023-04064-z |
| Poly(dA:dT) | A potential anti-HIV-1 compound, Q308, inhibits HSV-2 infection and replicati... | 2023 | Biomed Pharmacother. | Zhang X. et al. | DOI: 10.1016/j.biopha.2023.114595 |
| OVA peptides | The lactate dehydrogenase (LDH) isoenzyme spectrum enables optimally controll... | 2023 | Sci Adv. | Chen X. et al. | DOI: 10.1126/sciadv.add9554 |
| CFA | The lactate dehydrogenase (LDH) isoenzyme spectrum enables optimally controll... | 2023 | Sci Adv. | Chen X. et al. | DOI: 10.1126/sciadv.add9554 |
| IL12elasti (p40::p35) | Fusion peptide is superior to co-expressing subunits for arming oncolytic her... | 2023 | Commun Med (Lond). | Fukuhara H. et al. | DOI: 10.1038/s43856-023-00270-4 |
| Anti-hIL-6 Neutralizing mAb | Indoxyl-sulfate activation of the AhR- NF-κB pathway promotes interleukin-6 s... | 2023 | J Mol Cell Cardiol. | Candellier A. et al. | DOI: 10.1016/j.yjmcc.2023.03.011 |
| ODN 2216 - TLR9 ligand | Type I interferon signaling in malignant blasts contributes to treatment effi... | 2023 | Cell Death Dis. | Holicek P. et al. | DOI: 10.1038/s41419-023-05728-w |
| Poly(I:C) HMW | Type I interferon signaling in malignant blasts contributes to treatment effi... | 2023 | Cell Death Dis. | Holicek P. et al. | DOI: 10.1038/s41419-023-05728-w |
| B16-Blue™ ISG Cells | Epigenetic state determines the in vivo efficacy of STING agonist therapy. | 2023 | Nat Commun. | Falahat R. et al. | DOI: 10.1038/s41467-023-37217-1 |
| Zeocin® | Epigenetic state determines the in vivo efficacy of STING agonist therapy. | 2023 | Nat Commun. | Falahat R. et al. | DOI: 10.1038/s41467-023-37217-1 |
| B16-Blue™ ISG-KO-STING Cells | Epigenetic state determines the in vivo efficacy of STING agonist therapy. | 2023 | Nat Commun. | Falahat R. et al. | DOI: 10.1038/s41467-023-37217-1 |
| Ionomycin | Multiple Immune Defects in Two Patients with Novel DOCK2 Mutations Result in ... | 2023 | J Clin Immunol. | Li W. et al. | DOI: 10.1007/s10875-023-01466-y |
| Zeocin® | A novel Reelin construct, R36, recovered behavioral deficits in the heterozyg... | 2023 | Eur J Neurosci. | Morrill N.K. et al. | DOI: 10.1111/ejn.15971 |
| LumiKine™ Xpress mIFN-β 2.0 | Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. | 2023 | Cell Rep. | Heath B.R. et al. | DOI: 10.1016/j.celrep.2023.112303 |
| Puromycin | Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. | 2023 | Cell Rep. | Heath B.R. et al. | DOI: 10.1016/j.celrep.2023.112303 |
| ISD | Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. | 2023 | Cell Rep. | Heath B.R. et al. | DOI: 10.1016/j.celrep.2023.112303 |
| ISD | Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. | 2023 | Cell Rep. | Heath B.R. et al. | DOI: 10.1016/j.celrep.2023.112303 |
| 2’3’-cGAM(PS)2 (Rp/Sp) | Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. | 2023 | Cell Rep. | Heath B.R. et al. | DOI: 10.1016/j.celrep.2023.112303 |
| 2'3'-cGAMP | Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. | 2023 | Cell Rep. | Heath B.R. et al. | DOI: 10.1016/j.celrep.2023.112303 |